Phreesia (PHR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

$30,000 of PHREESIA INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Lobbying related to patient reported quality ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on PHR: Phreesia NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Phreesia stock opened at $27.12 on Thursday. The company’s 50-day moving average price is $23.18 and its 200-day moving average price is $22.71. The company has a quick ratio of 1.77, a current ...

Even though Visual Look Up can be very useful, some people might consider it a hidden iPhone feature, as it's really easy to ...

Analyst Ryan MacDonald from Needham maintained a Buy rating on Phreesia (PHR – Research Report) and keeping the price target at $29.00. Discover outperforming stocks and invest smarter with Top ...

Despite spending hours behind the wheel, most drivers remain clueless about certain dashboard warning symbols. One such ...

Phreesia (PHR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 6.1% of OptimizeRx shares are owned by insiders.

Phreesia, Inc. (NYSE:PHR), a leading healthcare technology company specializing in patient intake management and workflow optimization, has been garnering attention from analysts and investors ...